Researchers have developed a CRISPR-CAS base editing approach to treat trinucleotide repeat disorders by introducing protective interruptions into...

Scientists have developed a new adenine base editor (ABE) that matches the efficiency of the widely used ABE8e while offering significantly improved...

A team of academic and industry scientists have developed and delivered what may be the world’s first mRNA-based, patient-specific CRISPR therapy for...

Rather than correcting the main mutation that causes the disease, Italian researchers restored CFTR function by inserting naturally occurring,...

Eight months after dosing the first patient with BEAM-302, Beam Therapeutics has shared exciting safety and efficacy data indicating that a...

Researchers at ETH Zürich have introduced a combined base and prime editing approach to explore the mutational landscape of the epithelial growth...

A novel engineered TadA ortholog-derived cytosine base editor (aTdCBE) can overcome existing limitations in motif preferences and adenosine activity...

Researchers have engineered a minimal type I-F2 CRISPR-Cas system capable of transcriptional activation and base editing in human cells. This...